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Abstract
Background: Larger infarct size measured by creatine kinase (CK)-MB release is associated with higher mortality
and has been used as an important surrogate endpoint in the evaluation of new treatments for ST-segment
elevation myocardial infarction (STEMI). Traditional approaches to quantify infarct size include the observed CK-MB
peak and calculated CK-MB area under the curve (AUC). We evaluated alternative approaches to quantifying infarct
size using CK-MB values, and the relationship between infarct size and clinical outcomes.
Methods: Of 1,850 STEMI patients treated with reperfusion therapy in the COMplement inhibition in Myocardial
infarction treated with Angioplasty (COMMA) (percutaneous coronary intervention (PCI)-treated) and the
COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) (fibrinolytic-treated) trials,
1,718 (92.9%) (COMMA, n = 868; COMPLY, n = 850) had at least five of nine protocol-required CK-MB measures. In
addition to traditional methods, curve-fitting techniques were used to determine CK-MB AUC and estimated peak
CK-MB. Cox proportional hazards modeling assessed the univariable associations between infarct size and mortality,
and the composite of death, heart failure, shock and stroke at 90 days.
Results: In COMPLY, CK-MB measures by all methods were significantly associated with higher mortality (hazard
ratio range per 1,000 units increase: 1.09 to 1.13; hazard ratio range per 1 standard deviation increase: 1.41 to 1.62;
P <0.01 for all analyses). In COMMA, the associations were similar but did not reach statistical significance. For the
composite outcome of 90-day death, heart failure, shock and stroke, the associations with all CK-MB measures were
statistically significant in both the COMMA and COMPLY trials.
Conclusions: Sophisticated curve modeling is an alternative to infarct-size quantification in STEMI patients, but it
provides information similar to that of more traditional methods. Future studies will determine whether the same
conclusion applies in circumstances other than STEMI, or to studies with different frequencies and patterns of
CK-MB data collection.
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Background
The relationship between creatine kinase (CK)-MB
measured in the blood and infarct size has been well-
established through both pathological and imaging cor-
relations [1-8]. Furthermore, infarct size, measured by
release of CK-MB for example, is associated with short-
and long-term cardiovascular complications such as
cardiac death, reinfarction, congestive heart failure,
stroke and unstable angina requiring hospitalization
[9-19]. Infarct size determined by other methods of
quantification, such as single-photon emission computed
tomography, left ventricular angiography, echocardio-
gram and contrast-enhanced magnetic resonance im-
aging, have also been associated with subsequent clinical
outcomes in patients with ST-segment elevation myocar-
dial infarction (STEMI) [8,20-22].
Based on these known relationships, CK-MB is an im-
portant surrogate endpoint in the evaluation of new
treatments for STEMI. However, there has been debate
about what is the best method for quantifying CK-MB
release over the first 72 hours in patients with STEMI.
Thus, the optimal method for quantifying infarct size
using CK-MB is unknown, as is the nature of the rela-
tionships between infarct size and clinical outcomes
according to the method used. Therefore, we examined
the relationships between infarct size (quantified by mul-
tiple methods) using CK-MB and clinical outcomes in
patients with STEMI who were enrolled in two phase II
randomized clinical trials.
Methods
We studied 1,850 patients with STEMI treated with
reperfusion therapy who were enrolled in the COMplement
inhibition in Myocardial infarction treated with Angioplasty
(COMMA) (n = 929; PCI-treated) and COMPlement inhib-
ition in myocardial infarction treated with thromboLYtics
(COMPLY) (n = 921; fibrinolytic-treated) trials. These trials’
methods have been previously published [23,24]. In brief,
the primary objective of COMMA was to determine
whether treatment of acute STEMI within 6 hours of onset
of symptoms with 1. a bolus of pexelizumab and reperfu-
sion therapy with percutaneous transluminal coronary
angioplasty (PTCA), or 2. a bolus and infusion of
pexelizumab and PTCA reperfusion therapy, was superior
to PTCA reperfusion therapy alone in decreasing infarct
size. The primary objective of COMPLY was to determine
whether treatment of acute STEMI within 6 hours of onset
of symptoms with 1. a bolus of pexelizumab and thrombo-
lytic reperfusion therapy, or 2. a bolus and infusion of
pexelizumab and thrombolytic reperfusion therapy, was su-
perior to fibrinolytic reperfusion therapy alone in decreas-
ing infarct size. In both COMMA and COMPLY, CK-MB
values were measured at baseline prior to study drug ad-
ministration, and then at 1.5, 4, 8, 12, 16, 24, 36, 48 and 72
hours postinfusion of the bolus of study drug. In these stud-
ies, all CK-MB measures were performed in a central core
laboratory using a mass assay.
The CARDINAL trials complied with the Declaration
of Helsinki. All patients enrolled provided written in-
formed consent, and the trial was approved by the
institutional review boards and ethics committees of
participating sites. Use of trial data for the current ana-
lyses was approved by the institutional review board of
the Duke University Medical Center under protocol
number PRO00005720.
Statistical methods
After excluding 132 patients who did not have at least
five serial CK-MB measures (61 from COMMA and 71
from COMPLY), our final analysis population included
1,718 STEMI patients. We determined the observed
CK-MB peak numerical value from among the available
CK-MB measures and calculated the observed CK-MB
area under the curve (AUC) using the standard trapezoidal
method. In addition, we used modeling techniques to esti-
mate the CK-MB AUC and fitted peak CK-MB values, as
described in the following section. All individual data points
were used to fit the models in our analyses.
CK-MB curve modeling
Shell et al. [25] first described the use of the log-normal
curve to express the pattern of CK-MB values for a given
person over time. Vollmer et al. [26] compared several
different models to describe this same pattern, including
one that they indicated was equivalent to the log-normal
curve. In fact, that curve was similar but not equivalent.
They also included the 2-compartment model, the
gamma model and the model of Schwerdt et al. [27].
Vollmer et al. concluded that their version of the log-
normal model provided a better fit than the other
models. The general form of the log-normal model is as
follows:
y ¼ γ þ β








for t > 0; y
¼ γ for t≤0: ð1Þ
If there is reason to believe that the infarct does not
start at time zero but rather at an onset time δ (δ can be
positive or negative), then the model becomes as follows:
y ¼ γ þ β







σ t−δð Þ for t > δ; y
¼ γ for t≤δ: ð2Þ
All of the parameters can be estimated using standard
maximum likelihood methods, except for δ. If we fix δ, a
very good general method for obtaining least squares
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estimates of the remaining parameters of a model is
the modified Gauss-Newton method, as described by
Hartley [28]. The sum of squares of error can be com-
puted for each δ and the δ producing the minimum
error is the optimal estimate. An example of the fit for a
given patient in COMMA is shown in Figure 1.
The parameter δ can be interpreted as the time to the
onset of the event (as measured by the marker). The
parameter γ is the estimate of the background CK-MB
level for a particular individual. The parameter μ deter-
mines where the curve peaks. Although this parameter
is usually the most important when working with log-
normally distributed data, it may be the least important
in modeling the time course of CK-MB. The parameter
σ determines how tight (wide) the curve is. If a drug re-
duces the washout time for CK-MB without affecting
the AUC, then this parameter might be a sensitive meas-
ure. The parameter β determines the total AUC above
background (over all time). The area above background
from time zero to time T is just as follows:
βfΦ Ln T–δð Þ–Ln μð Þ½ =σð Þ−Φ Ln −δÞ–Ln μð Þ=σð Þ½ g if δ < 0;
β Φ Ln T–δð Þ–Ln μð Þ½ =σð Þf g otherwise;
ð3Þ
where Φ(x) is the standard cumulative normal distribu-
tion function. If the total area is desired, then T × γ must
be added to the area. In this particular case, T = 72
hours.
The fitted peak can be obtained by evaluation of equa-
tion (1) or (2) at the timepoint defined by (4):
t ¼ δ þ μe−σ2 : ð4Þ
Analyses of clinical endpoints
We used Cox proportional hazards models to explore
the univariable association of CK-MB AUC and peak
values derived from both 1. observation and 2. modeling
with 90-day mortality and a 90-day composite of death,
heart failure, shock and stroke. Pexelizumab had a neu-
tral effect on infarct size in both the COMMA and
COMPLY studies; therefore, we did not account for the
study drug in our analyses. Statistical significance was
defined at the 2-sided α = 0.05 level. Data analyses were
performed with SAS software (version 8.2; SAS Institute,
Cary, NC, USA).
Sensitivity analysis
We performed a sensitivity analysis excluding patients
with Killip class IV and creatinine clearance (CrCl) <60
ml/min (COMMA, n = 201; COMPLY, n = 200), leaving
616 COMMA patients and 606 COMPLY patients to
test whether the relationships between CK-MB measures
and clinical outcomes were similar to those in the main
analysis.
Results
Data quality and model fitting
Table 1 gives the distribution of the number of CK-MB
samples per patient. The majority of patients in both
studies had between eight and ten CK-MB measures.
COMMA trial
Of the 61 patients who did not have at least five CK-MB
values (6.6% of the total population of patients with
CK-MB data), 13 patients died and one patient was
discharged during the first 72 hours. Of the 868 patients
who had five or more CK-MB levels, 817 were analyzed
Figure 1 Example of log-normal cumulative distribution fitted to COMMA. CK, creatine kinase.
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(exclusions for the COMMA analyses are provided in
Table 2).
COMPLY trial
Of the 71 patients who did not have five readings (7.7% of
the total population of patients with CK-MB data), 36 pa-
tients died and one patient was discharged during the first
72 hours. Of the 850 patients who had five or more CK-MB
levels, 806 were analyzed (exclusions are shown in Table 3).
Clinical outcomes
In the COMPLY trial, there were 49 deaths and 123
composite outcomes. In the COMMA trial, there were
only 19 deaths and 72 composite clinical events. In the
COMPLY trial, all CK-MB measures were significantly
associated with higher rates of 90-day mortality (Table 4).
In the COMMA trial, the associations were nearly the
same as in the COMPLY trial but failed to reach statis-
tical significance (Table 4). For the composite outcome
of 90-day death, heart failure, shock and stroke, the as-
sociations with all CK-MB measures were statistically
significant in both the COMMA and COMPLY trials
(Table 5). For each of these analyses, results were similar
when patients with Killip class IV and CrCl <60 ml/min
were excluded from the analysis (data not shown).
Overall, larger infarct size (per each 1000 units increase
in CK-MB) was associated with an approximate 10%
increased risk of death and composite of death, heart
failure, shock and stroke at 90 days (Tables 4 and 5). To
compare how various measures of CK-MB affected
90-day outcomes, we rescaled each measure in units of
its standard deviation and evaluated hazard ratios per in-
crease of one standard deviation. As Table 4 shows, the
magnitude of association with 90-day outcomes was gener-
ally similar between model-derived and observed CK-MB
measures. The estimated hazard ratios of 90-day outcomes
associated with an increase of one standard deviation in
CK-MB AUC (whether observed or model-derived) were
larger than hazard ratios associated with increase in peak
CK-MB (whether observed or model-derived). However,
this finding was not statistically significant.
In COMPLY, all four measures of infarct size were
highly correlated with each other (correlation ≥0.93). In
COMMA, observed AUC and peak and estimated AUC
were highly correlated (correlation ≥0.96); however, the
correlations between estimated peak and three other
measures were much lower (correlations 0.51 to 0.56).
Discussion
Biomarkers such as CK-MB are used for diagnosis of
myocardial infarction (MI), but they can also be used to
estimate infarct size as a surrogate endpoint in clinical
trials of new treatments for MI [6,29-33]. Many methods
are used to determine infarct size, but little comparative
evidence exists as to which method best describes the
relationship of infarct size with meaningful clinical out-
comes, including mortality. Our results show that, in
general, the association of larger infarct size and worse
clinical outcomes, including mortality, is significant and
similar using multiple observed and derived measures of
infarct size based on CK-MB.
The use of infarct size as a surrogate outcome in phase
II clinical trials as a preliminary estimate of treatment
Table 1 Distribution of samples per patient
Number of
samples
Number (%) of patients
COMMA COMPLY
<5 61 (6.6) 71 (7.7)
5 17 (1.8) 11 (1.2)
6 49 (5.3) 20 (2.2)
7 113 (12.2) 35 (3.8)
8 233 (25.1) 141 (15.3)
9 453 (49.8) 639 (69.4)
10 3 (0.3) 4 (0.4)
COMMA, COMplement inhibition in Myocardial infarction treated with
Angioplasty; COMPLY, COMPlement inhibition in myocardial infarction treated
with thromboLYtics.
Table 2 Summary of exclusions in the analyses of
COMMA patients
Placebo Bolus Bolus + infusion
Patients with available CK-MB valuesa 302 311 316
Excluded patients
<5 points 18 20 23
No infarct 12 8 5
Could not fit 2 0 0
Delayed infarct 5 2 5
Second infarct 6 3 3
Final sample size for CK-MB analysis 259 278 280
CK, creatine kinase; COMMA, COMplement inhibition in Myocardial infarction
treated with Angioplasty. aPatients with at least 5 serial CK-MB measures.
Table 3 Summary of exclusions in the analyses of
COMPLY patients
Placebo Bolus Bolus + infusion
Patients with available CK-MB valuesa 307 303 311
Excluded patients
<5 points 23 23 25
No infarct 6 8 8
Could not fit 0 1 1
Delayed infarct 2 2 2
Second infarct 4 5 5
Final sample size for CK-MB analysis 272 264 270
CK, creatine kinase; COMPLY, COMPlement inhibition in myocardial infarction
treated with thromboLYtics. aPatients with at least 5 serial CK-MB measures.
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effect is predicated on the previously demonstrated
relationship between CK-MB and infarct size [4,5,7,8],
and between infarct size and meaningful clinical out-
comes [8-22]. Thus, it is important to define the most
accurate and reliable method to estimate infarct size
using CK-MB measures as surrogate endpoints in clin-
ical trials of treatment effect. Our main goal in the
present study was to illustrate methodological variations
in the use of CK-MB to estimate infarct size, and to
explore the relationship between infarct size (determined
by these various methods) and clinical outcomes. We
believe the insights from our work will be of particular
relevance for phase I and II studies. In addition, we be-
lieve the questions we addressed and our results may be
applicable to troponin measures as well.
Estimating infarct size based on measurements of
CK-MB in blood has inherent challenges. First, the fact
that pathological findings are the confirmatory and gold
standard criteria for MI size is a limitation per se;
however, using enzymatic measurement in this setting
may underestimate infarct size from 14% to 47% of the
time, especially if not all CK-MB values are available
[34]. Despite this, a previous study in patients who did
not receive reperfusion therapy reported good correl-
ation between the enzymatic estimates of infarct size
based on CK-MB and pathological measurements [35].
Most importantly, the time-activity curve of CK-MB in
the bloodstream is influenced by reperfusion, and be-
cause reperfusion itself influences infarct size, it may
complicate the estimation of infarct size by CK-MB ana-
lysis [5,7,33]. In our study, all patients underwent reper-
fusion. Thus, any possible change in the CK-MB-release
ratio between reperfused and not reperfused patients or
challenges in interpreting the results based on such het-
erogeneity was avoided. One might have expected that
there would be more heterogeneity in reperfusion speed
or completeness among fibrinolytic-treated patients in
COMPLY than in PCI-treated patients in COMMA, and
thus, a less-tight relationship with outcomes. However,
the opposite was observed. Because there were many
more events in COMPLY than in COMMA, while the
effect sizes were comparable, we believe the most likely
explanation for the lack of significance in COMMA was
one of statistical power.
Some believe that using cumulative CK-MB value is
more accurate to estimate MI size; however, cumulative
Table 4 Univariable associations of infarct size determined by various methods with 90-day mortality









Total CK-MB AUC, 0 to 72 hours from randomization estimated by
curve modelinga
per 1000 units 1.07 2.76 1.09 26.05
(0.99 to 1.17) (0.10) (1.06 to 1.13) (<0.01)
per 1 SD 1.35 1.58
(0.95 to 1.92) (1.33 to 1.88)
Estimated peaka
per 100 units 1.02 0.76 1.12 16.41
(0.98 to 1.07) (0.38) (1.06 to 1.19) (<0.01)
per 1 SD 1.10 1.41
(0.89 to 1.36) (1.20 to 1.67)
Observed trapezoidal CK-MB AUC
per 1000 units 1.09 4.61 1.10 29.04
(1.01 to 1.19) (0.03) (1.06 to 1.14) (<0.01)
per 1 SD 1.45 1.62
(1.03 to 2.03) (1.36 to 1.93)
Observed peak
per 100 units 1.16 3.75 1.13 16.26
(1.00 to 1.34) (0.05) (1.06 to 1.19) (<0.01)
per 1 SD 1.41 1.41
(1.00 to 2.00) (1.19 to 1.66)
aEstimated from the log-normal model. AUC, area under the curve; CI, confidence interval; CK, creatine kinase; COMMA, COMplement inhibition in Myocardial
infarction treated with Angioplasty; COMPLY, COMPlement inhibition in myocardial infarction treated with thromboLYtics; SD, standard deviation.
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value requires serial acquisition of blood samples, which
is both costly and time-consuming.
We found that the log-normal model we used to
estimate AUC and peak CK-MB did an outstanding job
of describing the time course of CK-MB readings in
patients having a single infarct. We also showed that the
observed CK-MB measures (AUC and peak) and mea-
sures obtained from sophisticated curve fitting had com-
parable associations with endpoints of 90-day death and
90-day death, heart failure, shock or stroke. However,
this may not be true in studies in which CK-MB values
are measured less often. At least five CK-MB measure-
ments are necessary to fit a log-normal model for the
CK-MB curve. It is still possible to calculate observed
CK-MB AUC using fewer than five measurements, but
the validity is questionable. Given the similarity in
relationships with clinical outcomes, our results suggest
that the method selected for quantifying infarct size as a
surrogate endpoint in clinical trials of STEMI treatment
can vary without compromising validity or generalizability
of the trial results, depending on the following: the oper-
ational needs and capacity of the trial and its sites,
available funding, and the quantitative skills and expertise
of the trial team.
Strengths and limitations
COMMA and COMPLY patients were STEMI patients
enrolled shortly after onset of MI symptoms, and the
majority had at least eight CK-MB samples collected
within 72 hours of enrollment. Thus, collecting CK-MB
readings over time and using them as a primary end-
point measure in early-phase clinical trials is clearly feas-
ible. Further, the dataset itself was of extremely high
quality. More than 7200 CK-MB measurements were
taken from more than 900 patients and the number of
questionable values was extremely small. However, it is
unknown whether our conclusions apply to studies with
different frequencies and patterns of CK-MB data collec-
tion or to non-STEMI populations. We did not collect
information about skeletal muscle disease, but we be-
lieve such cases would have been rare in these trials and
would not have substantially influenced our results.
Finally, although we believe that the methods and issues
that we described and analyzed in the current study may
Table 5 Univariable associations of infarct size determined by various methods with 90-day composite of mortality,
heart failure, shock and stroke









Total CK-MB AUC 0 to 72 hours from randomization estimated by
curve modelinga
per 1000 units 1.14 53.08 1.08 48.31
(1.10 to 1.18) (<0.001) (1.06 to 1.11) (<0.001)
per 1 SD 1.74 1.51
(1.50 to 2.02) (1.35 to 1.70)
Estimated peaka
per 100 units 1.03 15.34 1.11 29.87
(1.02 to 1.05) (<0.001) (1.07 to 1.15) (<0.001)
per 1 SD 1.15 1.36
(1.07 to 1.24) (1.22 to 1.53)
Observed trapezoidal CK-MB AUC
per 1000 units 1.15 55.76 1.09 50.26
(1.11 to 1.19) (<0.001) (1.06 to 1.11) (<0.001)
per 1 SD 1.79 1.53
(1.53 to 2.08) (1.36 to 1.73)
Observed peak
per 100 units 1.26 45.96 1.11 30.05
(1.18 to 1.34) (<0.001) (1.07 to 1.16) (<0.001)
per 1 SD 1.72 1.36
(1.47 to 2.01) (1.22 to 1.52)
aEstimated from the log-normal model. AUC, area under the curve; CI, confidence interval; CK, creatine kinase; COMMA, COMplement inhibition in Myocardial
infarction treated with Angioplasty; COMPLY, COMPlement inhibition in myocardial infarction treated with thromboLYtics; SD, standard deviation.
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be applied for troponin as well, we did not have troponin
data (or available samples) to confirm this hypothesis.
Conclusions
Sophisticated curve modeling of serial CK-MB measures
in STEMI patients provides an alternative method of
quantifying infarct size, and it produces results that are
comparable to more standard methods used in deter-
mining observed peak or AUC of CK-MB; however, it
requires intensive serial sampling regimens that may not
be feasible in all trials.
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